Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA GENE THERAPY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER FIVE ANALYSIS
5 UPDATE ON GERMLINE GENE THERAPY
5.1 GERMLINE GENE THERAPY
6 MIDDLE EAST & AFRICA GENE THERAPY MARKET, MO
6.1 DRIVERS
6.1.1 NOVEL APPROACHES TO GENE THERAPY
6.1.2 INCREASING PREVALENCE OF GENETIC DISORDERS
6.1.3 THE GROWING INVESTMENT BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
6.1.4 GROWING DEMAND FOR PERSONALIZED MEDICINE
6.2 RESTRAINTS
6.2.1 HIGH COST OF GENE THERAPY
6.2.2 ETHICAL AND SAFETY CONCERNS
6.2.3 COMPLEXITY OF GENE THERAPY
6.3 OPPORTUNITIES
6.3.1 RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS
6.3.2 RISING APPROVAL FOR GENE THERAPY PRODUCTS
6.4 CHALLENGES
6.4.1 STRINGENT REGULATIONS FOR GENE THERAPY PRODUCTS
6.4.2 LONG-TERM SAFETY AND EFFICACY
7 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY VECTOR TYPE
7.1 OVERVIEW
7.2 VIRAL VECTOR
7.2.1 ADENOVIRUS
7.2.2 RETROVIRUS
7.2.3 LENTIVIRUS
7.2.4 ADENO-ASSOCIATED VIRUS
7.2.5 VACCINIA VIRUS
7.2.6 HERPES SIMPLEX VIRUS
7.2.7 OTHERS
7.3 NON-VIRAL VECTOR
7.3.1 LIPOFECTION
7.3.2 INJECTION OF NAKED DNA
8 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY METHOD
8.1 OVERVIEW
8.2 EX-VIVO
8.3 IN-VIVO
9 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 ONCOLOGICAL DISORDERS
9.3 CARDIOVASCULAR DISEASES
9.4 INFECTIOUS DISEASES
9.5 RARE DISEASES
9.6 NUEROLOGICAL DISORDERS
9.7 OTHER DISEASES
10 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY END USER
10.1 OVERVIEW
10.2 CANCER INSTITUTES
10.3 HOSPITALS
10.4 RESEARCH INSTITUTES
10.5 OTHERS
11 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY REGION
11.1 MIDDLE EAST AND AFRICA
11.1.1 SOUTH AFRICA
11.1.2 REST OF MIDDLE EAST AND AFRICA
12 MIDDLE EAST & AFRICA GENE THERAPY MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
13 COMPANY PROFILES
13.1 BIOGEN
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 SWOT ANALYSIS
13.1.5 PRODUCT PORTFOLIO
13.1.6 RECENT DEVELOPMENT
13.2 KITE PHARMA
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 COMPANY SHARE ANALYSIS
13.2.4 SWOT ANALYSIS
13.2.5 PRODUCT PORTFOLIO
13.2.6 RECENT DEVELOPMENT
13.3 NOVARTIS AG
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 SWOT ANALYSIS
13.3.5 PRODUCT PORTFOLIO
13.3.6 RECENT DEVELOPMENTS
13.4 BRISTOL-MYERS SQUIBB COMPANY.
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 COMPANY SHARE ANALYSIS
13.4.4 SWOT ANALYSIS
13.4.5 PRODUCT PORTFOLIO
13.4.6 RECENT DEVELOPMENT
13.5 OXFORD BIOMEDICA
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 COMPANY SHARE ANALYSIS
13.5.4 SWOT ANALYSIS
13.5.5 PRODUCT PORTFOLIO
13.5.6 RECENT DEVELOPMENTS
13.6 AGC BIOLOGICS
13.6.1 COMPANY SNAPSHOT
13.6.2 PRODUCT PORTFOLIO
13.6.3 RECENT DEVELOPMENT
13.7 ANGES, INC
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENT
13.8 AMGEN INC.
13.8.1 COMPANY SNAPSHOT
13.8.2 REVENUE ANALYSIS
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENT
13.9 BLUEBIRD BIO, INC.
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENT
13.1 CHIESI FARMACEUTICI S.P.A
13.10.1 COMPANY SNAPSHOT
13.10.2 REVENUE ANALYSIS
13.10.3 PRODUCT PORTFOLIO
13.10.4 RECENT DEVELOPMENT
13.11 DENDREON PHARMACEUTICALS LLC
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENT
13.12 ENZYVANT THERAPEUTICS GMBH
13.12.1 COMPANY SNAPSHOT
13.12.2 RODUCT PORTFOLIO
13.12.3 RECENT DEVELOPMENT
13.13 FERRING B.V.
13.13.1 COMPANY SNAPSHOT
13.13.2 PRODUCT PORTFOLIO
13.13.3 RECENT DEVELOPMENT
13.14 JANSSEN PHARMACEUTICALS, INC.
13.14.1 COMPANY SNAPSHOT
13.14.2 PRODUCT PORTFOLIO
13.14.3 RECENT DEVELOPMENT
13.15 MALLINCKRODT.
13.15.1 COMPANY SNAPSHOT
13.15.2 REVENUE ANALYSIS
13.15.3 PRODUCT PORTFOLIO
13.15.4 RECENT DEVELOPMENT
13.16 ORCHARD THERAPEUTICS PLC.
13.16.1 COMPANY SNAPSHOT
13.16.2 REVENUE ANALYSIS
13.16.3 PRODUCT PORTFOLIO
13.16.4 RECENT DEVELOPMENT
13.17 SHANGHAI SUNWAY BIOTECH CO., LTD.
13.17.1 COMPANY SNAPSHOT
13.17.2 PRODUCT PORTFOLIO
13.17.3 RECENT DEVELOPMENT
13.18 SIBONO
13.18.1 COMPANY SNAPSHOT
13.18.2 PRODUCT PORTFOLIO
13.18.3 RECENT DEVELOPMENT
13.19 SPARK THERAPEUTICS, INC.
13.19.1 COMPANY SNAPSHOT
13.19.2 PRODUCT PORTFOLIO
13.19.3 RECENT DEVELOPMENT
13.2 UNIQURE NV.
13.20.1 COMPANY SNAPSHOT
13.20.2 REVENUE ANALYSIS
13.20.3 PRODUCT PORTFOLIO
13.20.4 RECENT DEVELOPMENT
14 QUESTIONNAIRE
15 RELATED REPORTS
List of Table
TABLE 1 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA EX-VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA IN –VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA ONCOLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA RARE DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA NEUROLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA OTHER DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA CANCER INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA HOSPITALS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA RESEARCH INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA OTHERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 28 SOUTH AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 29 SOUTH AFRICA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 30 SOUTH AFRICA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
TABLE 31 SOUTH AFRICA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION)
TABLE 32 SOUTH AFRICA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 33 SOUTH AFRICA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 34 REST OF MIDDLE EAST AND AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 MIDDLE EAST & AFRICA GENE THERAPY MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA GENE THERAPY MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA GENE THERAPY MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA GENE THERAPY MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA GENE THERAPY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA GENE THERAPY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA GENE THERAPY MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 MIDDLE EAST & AFRICA GENE THERAPY MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA GENE THERAPY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA GENE THERAPY MARKET: SEGMENTATION
FIGURE 11 THE INCREASING PREVALENCE OF GENETIC DISORDERS AND GROWING DEMAND FOR PERSONALIZED MEDICINE ARE EXPECTED TO DRIVE THE GROWTH OF THE MIDDLE EAST & AFRICA GENE THERAPY MARKET FROM 2023 TO 2030
FIGURE 12 THE VIRAL VECTOR SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA GENE THERAPY MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA GENE THERAPY MARKET
FIGURE 14 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY VECTOR TYPE, 2022
FIGURE 15 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY VECTOR TYPE, 2023-2030 (USD MILLION)
FIGURE 16 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY VECTOR TYPE, CAGR (2023-2030)
FIGURE 17 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY VECTOR TYPE, LIFELINE CURVE
FIGURE 18 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY METHOD, 2022
FIGURE 19 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY METHOD, 2023-2030 (USD MILLION)
FIGURE 20 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY METHOD, CAGR (2023-2030)
FIGURE 21 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY METHOD, LIFELINE CURVE
FIGURE 22 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY APPLICATION, 2022
FIGURE 23 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 24 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 25 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 26 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY END USER, 2022
FIGURE 27 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 MIDDLE EAST & AFRICA GENE THERAPY MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 MIDDLE EAST AND AFRICA GENE THERAPY MARKET: SNAPSHOT (2022)
FIGURE 31 MIDDLE EAST AND AFRICA GENE THERAPY MARKET: BY COUNTRY (2022)
FIGURE 32 MIDDLE EAST AND AFRICA GENE THERAPY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 33 MIDDLE EAST AND AFRICA GENE THERAPY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 34 MIDDLE EAST AND AFRICA GENE THERAPY MARKET: VECTOR TYPE (2023-2030)
FIGURE 35 MIDDLE EAST & AFRICA GENE THERAPY MARKET: COMPANY SHARE 2022 (%)
